Percutaneous Coronary Intervention
No increased CV, death risk with ticagrelor plus proton pump inhibitor therapy after PCI
Concomitant proton pump inhibitor plus ticagrelor monotherapy after PCI does not increase risk for all-cause death or an adverse CV event, in contrast with conventional post-PCI antiplatelet therapy, researchers reported.
Virtual, hybrid cardiac rehabilitation programs yield benefits similar to in-person
Patients referred for cardiac rehabilitation sessions experienced similar improvements in clinical outcomes whether the program was in-person, hybrid or virtual, including similar changes in 6-minute walk distance, researchers reported.
Steerable microcatheter nets FDA 510(k) clearance for neurologic, peripheral, coronary use
Bendit Technologies announced it received FDA 510(k) clearance for its steerable microcatheter platform for treatment in the neurologic, peripheral and coronary vasculature.
Sodium thiosulfate does not reduce infarct size vs. placebo after reperfusion for STEMI
WASHINGTON — Sodium thiosulfate, administered before and after reperfusion for STEMI, did not improve infarct size between 4 months and 2 years compared with placebo, a speaker reported.
FDA clears support catheter platform for coronary use
Transit Scientific announced the FDA cleared its support catheter platform for coronary use.
In PCI, FFR guidance noninferior to IVUS guidance for clinical outcomes at 2 years: FLAVOUR
WASHINGTON — In a head-to-head trial, PCI guided by fractional flow reserve was noninferior to PCI guided by IVUS for death, MI and revascularization at 2 years, researchers reported at the American College of Cardiology Scientific Session.
Complete revascularization may improve angina-related health in STEMI, multivessel CAD
WASHINGTON — Complete revascularization, as opposed to culprit lesion-only revascularization, was associated with better angina-related quality of life in patients with STEMI and multivessel CAD, a speaker reported.
Quality of life similar after FFR-guided PCI, CABG for three-vessel coronary disease
WASHINGTON — In patients with three-vessel CAD, those who underwent fractional flow reserve-guided PCI had similar quality of life at 1 year compared with those who underwent CABG, according to new data from the FAME 3 trial.
Pollen exposure before ACS hospitalization may negatively affect PCI outcomes
Although researchers could not associate pollen exposure with incident ACS, they did observe elevated in-hospital mortality after PCI following days of high pollen exposure prior to presentation.
Thrombocytopenia associated with worse outcomes after PCI
The presence of moderate to severe thrombocytopenia before PCI is associated with increased risk for in-hospital mortality and shorter time to repeat revascularization compared with no or mild thrombocytopenia, researchers reported.